News

Qiagen steps into NGS market
Enlarge image

BusinessGermanyNetherlands

Qiagen steps into NGS market

22.02.2013 - Molecular diagnostics and lab provider Qiagen is entering the highly competitive market of Next-Generation Sequencing (NGS) benchtop sequencers.

The company presented a sample-to-result Next-Generation Sequencing workflow designed for clinical research and diagnostics at the AGBT meeting in Florida. However, its sample preparation, newly introduced benchtop sequencer GeneReaderTM and bioinformatics solution is for research use only, as those are of its competitors Roche, Illumina and Life Technologies. However, the announcement suggested that the Dutch-German company’s NGS workflow is automated from primary sample to digital result.

"Next-generation sequencing is making a transformational impact on life science, but challenges are limiting more widespread adoption for clinical purposes," said Peer M. Schatz, CEO of QIAGEN. "The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content and services."

No sequencing firm currently has a NGS workflow that is simple and reliable enough for diagnostic purposes. However, all of them aim at establishing highly automated and inter-laboratory reproducible NGS procedures that can be used by non-specialists. The adoption of NGS in fields such as clinical research and diagnostics is still hampered by workflow challenges, manual sample preparation processes, the speed, comparability and quality of data analysis.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/qiagen-steps-into-ngs-market.html

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR15.48%
  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%

FLOP

  • MOLOGEN6.60 EUR-13.16%
  • WILEX2.15 EUR-1.83%
  • ADDEX3.40 CHF-1.16%

TOP

  • BIOFRONTERA2.92 EUR32.7%
  • BB BIOTECH157.00 EUR7.2%
  • ADDEX3.40 CHF6.6%

FLOP

  • PAION2.22 EUR-31.9%
  • CYTOS0.17 CHF-19.0%
  • MAGFORCE5.95 EUR-15.6%

TOP

  • SANTHERA84.30 CHF2248.2%
  • CO.DON2.84 EUR202.1%
  • PAION2.22 EUR161.2%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 22.10.2014